CN111544386A - Preparation method of oral liquid for reducing blood sugar - Google Patents
Preparation method of oral liquid for reducing blood sugar Download PDFInfo
- Publication number
- CN111544386A CN111544386A CN202010550842.XA CN202010550842A CN111544386A CN 111544386 A CN111544386 A CN 111544386A CN 202010550842 A CN202010550842 A CN 202010550842A CN 111544386 A CN111544386 A CN 111544386A
- Authority
- CN
- China
- Prior art keywords
- oral liquid
- rhizoma polygonati
- cinnamon
- blood sugar
- tartary buckwheat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a hypoglycemic oral liquid, which is prepared from the following raw materials (by weight portion) tartary buckwheat 34.52-43.87%, sea-buckthorn 1.84-11.02%, kudzu root 0.05-2.21%, Siberian solomonseal rhizome 20.47-27.65%, cinnamon 20.64-27.65%, gynura divaricata 0.52-2.15%, mulberry leaf 0.15-0.61%, deionized water: and (4) the balance. The healthy tea belongs to a product with homology of medicine and food, has reasonable proportion, proper taste and convenient taking, reduces blood sugar on the basis of not damaging liver and kidney organs of a diabetic, and is suitable for hyperglycemia crowds and the diabetic to drink; can effectively improve pathological change of liver tissue, inhibit activity of alpha-glucosidase in vivo, reduce generation of glucose, reduce blood sugar concentration, and repair liver injury by improving the ability of organism to remove free radicals.
Description
Technical Field
The invention relates to the field of health-care oral liquid, in particular to a preparation method of oral liquid for reducing blood sugar.
Background
It is well known that diabetes is a metabolic disease characterized by hyperglycemia due to insufficient insulin-secreting ability of a patient and a gradual decrease in insulin sensitivity of the body. In the past decades, the urbanization process of China has been rapidly developed, and the urbanization development is related to the change of life style of residents, such as lack of exercise, unhealthy diet, obesity and other environmental factors are related to the pathogenesis of diabetes, so that the number of diabetes patients in China is increased remarkably.
At present, no method for radically treating diabetes exists at home and abroad, and only a method for temporarily controlling and stabilizing blood sugar value by taking blood sugar-reducing medicines or injecting insulin is used. However, if a diabetic takes the hypoglycemic drug for a long time, the drug resistance of the pancreatic islet organs of the diabetic will be continuously enhanced, the dosage of the drug of the diabetic will be continuously increased, and finally, the diabetic not only brings great economic pressure to the diabetic, but also causes pain in the treatment process, and finally causes complications, such as foot gangrene, renal failure, heart disease, cerebrovascular disease, uremia and the like.
Disclosure of Invention
The invention aims to provide a health oral liquid which has good treatment effect on diabetics but has no toxic or side effect on the diabetics. The oral liquid adopts scientific formula, has suitable taste and convenient drinking, reduces fasting blood glucose on the basis of not damaging liver and kidney organs of the diabetic, and is suitable for hyperglycemia people and the diabetic to drink.
In order to achieve the purpose, the invention adopts the technical scheme that:
an oral liquid for reducing blood sugar is characterized in that: is prepared from the following raw materials (by weight portion) tartary buckwheat 34.52-43.87%, sea-buckthorn 1.84-11.02%, kudzu vine root 0.05-2.21%, Siberian solomonseal rhizome 20.47-27.65%, cinnamon 20.64-27.65%, gynura divaricata 0.52-2.15%, mulberry leaf 0.15-0.61%, deionized water: and (4) the balance.
Preferably, the oral liquid for reducing blood sugar is prepared from 41.64% of tartary buckwheat, 6.94% of sea-buckthorn, 1.00% of radix puerariae, 24.29% of rhizoma polygonati, 24.29% of cinnamon, 1.55% of gynura divaricata and 0.28% of mulberry leaves.
Preferably, the oral liquid for reducing blood sugar is prepared from 41.81% of tartary buckwheat, 6.97% of sea-buckthorn, 1.00% of radix puerariae, 24.39% of rhizoma polygonati, 24.39% of cinnamon, 1.17% of gynura divaricata and 0.28% of mulberry leaves.
Preferably, the blood sugar reducing oral liquid: is prepared from (by weight parts) radix Et rhizoma Fagopyri Tatarici 41.69%, fructus Hippophae 6.95%, radix Puerariae 1.00%, rhizoma Polygonati 24.32%, cortex Cinnamomi 24.32%, herba gynostemmatis segeti 1.17%, and folium Mori 0.56%.
A preparation method of the oral liquid for reducing blood sugar comprises the following specific steps:
the method comprises the following steps: firstly, weighing the following raw materials, namely 15g of tartary buckwheat, 10g of sea-buckthorn, 7.2g of kudzu root, 5g of rhizoma polygonati, 5g of cinnamon, 2.8g of gynura divaricata and 2g of mulberry leaf;
step two: washing radix Et rhizoma Fagopyri Tatarici, fructus Hippophae, radix Puerariae, rhizoma Polygonati, cortex Cinnamomi, herba Chelidonii and folium Mori with water, drying at constant temperature for 6-8 hr at 75-85 deg.C for 3-5 times;
step three: respectively mechanically pulverizing radix Et rhizoma Fagopyri Tatarici, fructus Hippophae, radix Puerariae, rhizoma Polygonati, cortex Cinnamomi, herba Chelidonii and folium Mori to 80-100 mesh;
step four: adding 7 raw materials of tartary buckwheat, sea buckthorn, kudzu root, rhizoma polygonati, cinnamon, gynura divaricata and mulberry leaf into 7 beakers filled with 900mL of deionized water respectively, putting the beakers into an ultrasonic instrument for water extraction, repeatedly extracting for 2-4 times, combining filtrates, and concentrating to 100 mL.
Step five: sterilizing the tartary buckwheat, the sea buckthorn, the kudzuvine root, the rhizoma polygonati, the cinnamon, the gynura divaricata and the mulberry leaf solution respectively under the sterilization condition of 100-140 ℃ for 10-30 min.
Step six: mixing sterilized radix Et rhizoma Fagopyri Tatarici, fructus Hippophae, radix Puerariae, rhizoma Polygonati, cortex Cinnamomi, herba Chelidonii and folium Mori solution under aseptic condition, and packaging.
Preferably, in the above method for preparing the oral liquid for reducing blood sugar, the drying conditions of the tartary buckwheat, the sea buckthorn, the kudzuvine root, the rhizoma polygonati, the cinnamon, the gynura divaricata and the mulberry leaf are 80 ℃, the drying is carried out for 8 hours at constant temperature each time, and the drying is carried out for 4 times; the grinding granularity of the tartary buckwheat, the sea buckthorn, the kudzuvine root, the rhizoma polygonati, the cinnamon, the gynura divaricata and the mulberry leaf is 100 meshes; respectively adding 7 raw materials of tartary buckwheat, sea buckthorn, kudzu vine root, rhizoma polygonati, cinnamon, gynura divaricata and mulberry leaf into 7 beakers filled with 900mL of deionized water, repeatedly extracting for 2 times, boiling for 1 time at 90 ℃, combining filtrates, and concentrating to 100 mL; the sterilization condition of the tartary buckwheat, the sea buckthorn, the kudzuvine root, the sealwort, the cinnamon, the gynura divaricata and the mulberry leaf solution is sterilization for 20min at 115 ℃; the tartary buckwheat, the sea buckthorn, the kudzuvine root, the rhizoma polygonati, the cinnamon, the gynura divaricata and the mulberry leaf solution are mixed and filled under the aseptic condition.
Preferably, in the above method for preparing the hypoglycemic oral liquid, the oral liquid is packaged by disposable brown bayonet bottles, each bottle is 10mL, and the oral liquid is packaged by external plastic oral liquid packaging boxes.
According to the invention, by scientific proportioning of the formula, the blood sugar values of hyperglycemia crowds and diabetes patients can be reduced, the harm of the hyperglycemia crowds and the diabetes patients to body organs caused by long-term administration of western medicines can be improved, and the formula has the following beneficial effects:
the health tea belongs to a pure traditional Chinese medicine product, is reasonable in proportion and proper in taste, can be brewed with warm water, is convenient to drink, can reduce blood sugar on the basis of not damaging liver and kidney organs of a diabetic, and is suitable for hyperglycemia crowds and the diabetic to drink;
the health tea has greatly changed taste, and the added sea buckthorn is rich in various amino acids and vitamins required by human body;
the polysaccharides in the kudzu root, the rhizoma polygonati, the cinnamon, the gynura divaricata and the mulberry leaves in the healthy tea have a protection effect on the liver, and the polysaccharides contained in the healthy tea raw materials have an inhibition effect on alanine aminotransferase and aspartate aminotransferase, so that the activity of the polysaccharides is obviously reduced, the pathological change of the liver tissue can be improved, and the polysaccharides contained in the healthy tea raw materials can improve the capability of clearing free radicals of the organism, so that the effect of repairing the liver injury is achieved.
Detailed Description
It is easily understood that according to the technical solution of the present invention, a person skilled in the art can propose various alternative structures and implementation ways without changing the spirit of the present invention. Therefore, the following detailed description is merely illustrative of the technical solutions of the present invention, and should not be construed as being all of the present invention or limiting or restricting the technical solutions of the present invention.
The invention provides a hypoglycemic oral liquid, which comprises the following raw materials by weight, 34.52-43.87% of tartary buckwheat, 1.84-11.02% of sea buckthorn, 0.05-2.21% of kudzu root, 20.47-27.65% of rhizoma polygonati, 20.64-27.65% of cinnamon, 0.52-2.15% of gynura divaricata, 0.15-0.61% of mulberry leaf and deionized water: and (4) the balance.
Specifically, the raw materials of the formula in the invention are described as follows:
buckwheat: is rich in selenium, can supplement selenium to human body naturally, is known as the king of five cereals, and has the efficacies of reducing blood sugar, blood pressure, blood fat, activating qi and blood and the like.
Sea-buckthorn: sea-buckthorn has high vitamin C content, and the vitamin C is a good name of vitamin C. Sea-buckthorn is widely used in many fields such as food, medicine and light industry. Modern medical research shows that seabuckthorn can reduce cholesterol, relieve angina attack and prevent and treat coronary atherosclerotic heart disease.
Kudzu root: is dried root of Pueraria lobata Ohwi of Leguminosae, commonly known as Pueraria lobata Ohwi. Has the functions of expelling pathogenic factors from muscles, allaying fever, promoting eruption, promoting the production of body fluid to quench thirst, invigorating yang and stopping diarrhea. It is commonly indicated for exterior syndrome with fever, stiffness and pain of neck and back, measles without adequate eruption, thirst due to fever, diabetes due to yin deficiency, dysentery due to heat-purging and diarrhea due to spleen deficiency.
Rhizoma polygonati: also named as rhizoma Polygonati and herba Coriandri. Is a medicinal plant, and has effects of invigorating spleen, moistening lung, and promoting fluid production. The rhizoma polygonati extract has a remarkable inhibiting effect on hyperglycemia caused by epinephrine.
Cinnamon: also named as Yugui and mu Gui. Is dried bark of Cinnamomum cassia of Lauraceae, and the bark is fragrant. The cinnamon polysaccharide in the cinnamon has obvious blood sugar reducing effect.
White seed vegetable: also called as 'Baibei pseudo-ginseng', has the efficacies of reducing blood sugar, clearing heat and cooling blood and the like.
Mulberry leaf: the mulberry leaf polysaccharide in the mulberry leaves has obvious blood sugar reducing effect, is rich in rare elements such as organic selenium and germanium, and has strong antioxidant activity.
The oral liquid is prepared from radix Et rhizoma Fagopyri Tatarici from Sichuan, fructus Hippophae from Gansu, radix Puerariae from Henan, rhizoma Polygonati from Jilin, cortex Cinnamomi from Guangdong, herba Lysimachiae Christinae from Guangdong, and folium Mori from Jiangsu.
By the scientific proportion of the formula, the blood sugar value of hyperglycemia crowds and diabetes patients can be reduced, and the harm of western medicines to body organs of the hyperglycemia crowds and the diabetes patients after long-term administration can be improved.
The preparation method of the hypoglycemic oral liquid in the preferred embodiment of the invention comprises the following steps:
the method comprises the following steps: firstly, weighing the following raw materials, namely 15g of tartary buckwheat, 10g of sea-buckthorn, 7.2g of kudzu root, 5g of rhizoma polygonati, 5g of cinnamon, 2.8g of gynura divaricata and 2g of mulberry leaf;
step two: washing radix Et rhizoma Fagopyri Tatarici, fructus Hippophae, radix Puerariae, rhizoma Polygonati, cortex Cinnamomi, herba Chelidonii and folium Mori with water, drying at constant temperature for 6-8 hr at 75-85 deg.C for 3-5 times;
step three: respectively mechanically pulverizing radix Et rhizoma Fagopyri Tatarici, fructus Hippophae, radix Puerariae, rhizoma Polygonati, cortex Cinnamomi, herba Chelidonii and folium Mori to 80-100 mesh;
step four: adding 7 raw materials of tartary buckwheat, sea buckthorn, kudzu root, rhizoma polygonati, cinnamon, gynura divaricata and mulberry leaf into 7 beakers filled with 900mL of deionized water respectively, putting the beakers into an ultrasonic instrument for water extraction, repeatedly extracting for 2-4 times, combining filtrates, and concentrating to 100 mL.
Step five: sterilizing the tartary buckwheat, the sea buckthorn, the kudzuvine root, the rhizoma polygonati, the cinnamon, the gynura divaricata and the mulberry leaf solution respectively under the sterilization condition of 100-140 ℃ for 10-30 min.
Step six: mixing sterilized radix Et rhizoma Fagopyri Tatarici, fructus Hippophae, radix Puerariae, rhizoma Polygonati, cortex Cinnamomi, herba Chelidonii and folium Mori solution under aseptic condition, and packaging.
In the second step of the preparation method of the oral liquid, the cell walls in the raw materials can be damaged by heating the raw materials at high temperature, so that the effective components in the raw materials can be extracted by water more easily, and the aim of sterilization is fulfilled. In the experimental process, the drying at the constant temperature of 80 ℃ has the advantages that the wall breaking effect of the raw materials is good, the temperature is continuously increased, the wall breaking effect is not greatly improved, and the energy consumption is increased. After each drying, ventilating and cooling to room temperature, heating and drying for 4 times, and rapidly heating is also favorable for improving the wall breaking effect of the raw materials. In the third step, the raw materials are mechanically crushed, and the crushing grain size is too coarse, so that the extraction effect is influenced; the ground particle size is too fine, so that the effective components in the raw materials can be more easily extracted by water, but more powder is deposited at the bottom in the extraction process, and the taste is influenced. Therefore, the extraction effect and the taste are balanced under the condition that the crushing granularity is 100 meshes. In the fourth step, ultrasonic extraction is repeated for 2 times, so as to crush the cell walls in the raw materials, and then boiling for 1 time, so that the effective components in the raw materials are better dissolved in the solvent. And step five, under the sterilization condition, the related quality standard of the tea bag meets the national standard, and the sterilization time is continuously prolonged, so that the energy consumption is increased.
The use method and the dosage of the oral liquid are as follows: the oral liquid is 10mL for each pill, and the daily dosage is 3 pills, 1 pill after breakfast, lunch and dinner.
In this example, the method for measuring the inhibition rate of α -glucosidase was as follows:
the method comprises the following steps: 2000. mu.L of 0.02moL/L phosphate buffer solution with pH 6.8 was weighed into a test tube, 400. mu.L of crude polysaccharide solution, 100. mu.L of 0.5mg/mL reduced glutathione solution, and 100. mu.L of 0.5u/mL alpha-glucosidase solution were added in this order, mixed well, and subjected to water bath at 37 ℃ for 10 min.
Step two: adding 40 μ L of 0.5mg/mL PNPG solution, mixing, and water bathing at 37 deg.C for 15 min.
Step three: adding 2000. mu.L of 0.1moL/L Na2CO3 solution, stopping the reaction, measuring the absorbance at the wavelength of 405nm, and marking as a sample A; replacing the sample with phosphate buffer solution, and measuring absorbance under the same conditions as sample A, and recording as A control; and (4) replacing the enzyme solution with phosphate buffer solution, and measuring absorbance under the same other conditions as the sample A, and marking as a blank of the sample A.
The inhibition rate of the sample A on the alpha-glucosidase is calculated according to the following formula:
the technical scope of the present invention is not limited to the above description, and those skilled in the art can make various changes and modifications to the above-described embodiments without departing from the technical spirit of the present invention, and such changes and modifications should fall within the protective scope of the present invention.
Example 1
The raw materials in the embodiment are washed, then placed in a drying box, dried for 6 hours at the constant temperature of 75 ℃, dried for 3 times at the constant temperature, mechanically crushed, sieved by a 80-mesh sieve, ultrasonically extracted for 2 times, extracted with water at the temperature of 90 ℃ for 1 time, and then transferred to an autoclave to be sterilized for 10 minutes at the temperature of 100 ℃, wherein the oral liquid is prepared by 30mL of rhizoma polygonati water extract, 30mL of cinnamon water extract, 15mL of tartary buckwheat water extract, 1mL of sea buckthorn water extract, 1mL of gynura divaricata water extract, 0.5mL of mulberry leaf water extract and 0.5mL of kudzu root water extract, the filling adopts disposable brown bayonet bottle packaging, each bottle is 10mL, and the external plastic oral liquid packaging box is used for packaging. The half inhibition concentration IC50 of the oral liquid with the mixture ratio to alpha-glucosidase is 1.322mg/mL, and the oral liquid tastes bitter.
Example 2
The raw materials in the embodiment are washed, then placed in a drying box, dried for 7 hours at the constant temperature of 80 ℃, dried for 4 times at the constant temperature, mechanically crushed, sieved by a 90-mesh sieve, ultrasonically extracted for 3 times, extracted with water at the temperature of 90 ℃ for 1 time, and then transferred to an autoclave to be sterilized for 20 minutes at the temperature of 115 ℃, the oral liquid is prepared by 40mL of rhizoma polygonati water extract, 40mL of cinnamon water extract, 25mL of tartary buckwheat water extract, 10mL of sea buckthorn water extract, 5mL of gynura divaricata water extract, 2mL of mulberry leaf water extract and 2mL of kudzu vine root water extract, the filling adopts disposable brown bayonet bottle packaging, 10mL of each bottle, and the external plastic oral liquid packaging box is used for packaging. The half inhibition concentration IC50 of the oral liquid with the mixture ratio to alpha-glucosidase is 0.947mg/mL, and the oral liquid tastes bitter.
Example 3
The raw materials in the embodiment are washed, then placed in a drying box, dried for 8 hours at the constant temperature of 85 ℃, dried for 5 times at the constant temperature, mechanically crushed, sieved by a 100-mesh sieve, ultrasonically extracted for 4 times, extracted with water at the temperature of 90 ℃ for 1 time, and then transferred to an autoclave for sterilization at the temperature of 120 ℃ for 30min, the oral liquid is prepared by 32mL of rhizoma polygonati water extract, 35mL of cinnamon water extract, 18mL of tartary buckwheat water extract, 3mL of sea buckthorn water extract, 2mL of gynura divaricata water extract, 1mL of mulberry leaf water extract and 1mL of radix puerariae water extract, the filling adopts disposable brown bayonet bottle packaging, 10mL of each bottle, and the external plastic oral liquid packaging box is used for packaging. The half inhibition concentration IC50 of the oral liquid with the proportion to alpha-glucosidase is 0.971mg/mL, and the oral liquid tastes slightly sweet.
Example 4
The raw materials in the embodiment are washed, then placed in a drying box, dried for 7 hours at the constant temperature of 75 ℃, dried for 4 times at the constant temperature, mechanically crushed, sieved by a 100-mesh sieve, ultrasonically extracted for 2 times, extracted with water at the temperature of 90 ℃ for 1 time, and then transferred to an autoclave for sterilization at the temperature of 120 ℃ for 20min, the oral liquid is prepared by 35mL of rhizoma polygonati water extract, 35mL of cinnamon water extract, 15mL of tartary buckwheat water extract, 5mL of sea buckthorn water extract, 3mL of gynura divaricata water extract, 2mL of mulberry leaf water extract and 2mL of kudzu vine root water extract, the filling adopts disposable brown bayonet bottle packaging, 10mL of each bottle, and the external plastic oral liquid packaging box is used for packaging. The half inhibition concentration IC50 of the oral liquid with the proportion on alpha-glucosidase is 0.825mg/mL, and the oral liquid tastes bitter.
Example 5
The raw materials in the embodiment are washed, then placed in a drying box, dried for 6 hours at the constant temperature of 80 ℃, dried for 4 times at the constant temperature, mechanically crushed, sieved by a 100-mesh sieve, ultrasonically extracted for 2 times, extracted with water at the temperature of 90 ℃ for 1 time, and then transferred to an autoclave for sterilization at the temperature of 130 ℃ for 20min, the oral liquid is prepared by mixing 38mL of rhizoma polygonati water extract, 30mL of cinnamon water extract, 20mL of tartary buckwheat water extract, 7mL of sea buckthorn water extract, 4mL of gynura divaricata water extract, 1mL of mulberry leaf water extract and 0.5mL of kudzu vine root water extract, the filling adopts disposable brown bayonet bottle packaging, each bottle is 10mL, and the external plastic oral liquid packaging box is used for packaging. The half inhibition concentration IC50 of the oral liquid with the proportion to alpha-glucosidase is 0.873mg/mL, and the oral liquid has proper taste.
Example 6
The raw materials in the embodiment are washed, then placed in a drying box, dried for 8 hours at the constant temperature of 85 ℃, dried for 5 times at the constant temperature, mechanically crushed, sieved by a 100-mesh sieve, ultrasonically extracted for 5 times, extracted with water at the temperature of 90 ℃ for 1 time, and then transferred to an autoclave for sterilization at the temperature of 140 ℃ for 20min, the oral liquid is prepared by modulating 40mL of rhizoma polygonati water extract, 38mL of cinnamon water extract, 22mL of tartary buckwheat water extract, 5mL of sea buckthorn water extract, 3mL of gynura divaricata water extract, 0.5mL of mulberry leaf water extract and 2mL of kudzu vine root water extract, the filling adopts disposable brown bayonet bottle packaging, each bottle is 10mL, and the external plastic oral liquid packaging box is used for packaging. The half inhibition concentration IC50 of the oral liquid with the mixture ratio to alpha-glucosidase is 0.892mg/mL, and the oral liquid has proper taste.
Example 7
The raw materials in the embodiment are washed, then placed in a drying box, dried for 8 hours at the constant temperature of 80 ℃, dried for 4 times at the constant temperature, mechanically crushed, sieved by a 90-mesh sieve, ultrasonically extracted for 4 times, extracted with water at the temperature of 90 ℃ for 1 time, and then transferred to an autoclave for sterilization at the temperature of 135 ℃ for 30min, wherein the oral liquid is prepared by 35mL of rhizoma polygonati water extract, 40mL of cinnamon water extract, 25mL of tartary buckwheat water extract, 9mL of sea buckthorn water extract, 2mL of gynura divaricata water extract, 1mL of mulberry leaf water extract and 1mL of kudzu vine root water extract, the filling adopts disposable brown bayonet bottle packaging, 10mL of each bottle, and the external plastic oral liquid packaging box is used for packaging. The half inhibition concentration IC50 of the oral liquid with the mixture ratio to alpha-glucosidase is 0.673mg/mL, and the oral liquid tastes bitter.
Example 8
The raw materials in the embodiment are washed by water, then are placed in a drying box, dried for 8 hours at the constant temperature of 80 ℃, dried for 4 times at the constant temperature, mechanically crushed, sieved by a 100-mesh sieve, ultrasonically extracted for 4 times, extracted by water at the temperature of 90 ℃ for 1 time, and then transferred to an autoclave for sterilization at the temperature of 120 ℃ for 20min, the oral liquid is prepared by 32mL of rhizoma polygonati water extract, 32mL of cinnamon water extract, 18mL of tartary buckwheat water extract, 4mL of sea buckthorn water extract, 5mL of gynura divaricata water extract, 0.5mL of mulberry leaf water extract and 1mL of kudzu vine root water extract, the filling adopts disposable brown bayonet bottle packaging, each bottle is 10mL, and the external plastic oral liquid packaging box is used. The half inhibition concentration IC50 of the oral liquid with the proportion to alpha-glucosidase is 0.628mg/mL, and the oral liquid has proper taste.
Example 9
The raw materials in the embodiment are washed, then placed in a drying box, dried for 7 hours at the constant temperature of 80 ℃, dried for 4 times at the constant temperature, mechanically crushed, sieved by a 100-mesh sieve, ultrasonically extracted for 3 times, extracted with water at the temperature of 90 ℃ for 1 time, and then transferred to an autoclave to be sterilized for 20 minutes at the temperature of 115 ℃, the oral liquid is prepared by 35mL of rhizoma polygonati water extract, 35mL of cinnamon water extract, 20mL of tartary buckwheat water extract, 5mL of sea buckthorn water extract, 4mL of gynura divaricata water extract, 1mL of mulberry leaf water extract and 1mL of kudzu vine root water extract, the filling adopts disposable brown bayonet bottle packaging, 10mL of each bottle, and the external plastic oral liquid packaging box is packaged. The half inhibition concentration IC50 of the oral liquid with the proportion to alpha-glucosidase is 0.404mg/mL, and the oral liquid has proper taste.
Example 10
The raw materials in the embodiment are washed, then placed in a drying box, dried for 8 hours at the constant temperature of 80 ℃, dried for 4 times at the constant temperature, mechanically crushed, sieved by a 100-mesh sieve, ultrasonically extracted for 2 times, extracted with water at the temperature of 90 ℃ for 1 time, and then transferred to an autoclave to be sterilized for 20 minutes at the temperature of 115 ℃, the oral liquid is prepared by 35mL of rhizoma polygonati water extract, 35mL of cinnamon water extract, 20mL of tartary buckwheat water extract, 5mL of sea buckthorn water extract, 3mL of gynura divaricata water extract, 1mL of mulberry leaf water extract and 1mL of kudzu vine root water extract, the filling adopts disposable brown bayonet bottle packaging, 10mL of each bottle, and the external plastic oral liquid packaging box is packaged. The half inhibition concentration IC50 of the oral liquid with the proportion to alpha-glucosidase is 0.399mg/mL, and the oral liquid has proper taste.
Example 11
The raw materials in the embodiment are washed, then placed in a drying box, dried for 8 hours at the constant temperature of 80 ℃, dried for 4 times at the constant temperature, mechanically crushed, sieved by a 100-mesh sieve, ultrasonically extracted for 2 times, extracted with water at the temperature of 90 ℃ for 1 time, and then transferred to an autoclave to be sterilized for 20 minutes at the temperature of 115 ℃, the oral liquid is prepared by 35mL of rhizoma polygonati water extract, 35mL of cinnamon water extract, 20mL of tartary buckwheat water extract, 5mL of sea buckthorn water extract, 3mL of gynura divaricata water extract, 2mL of mulberry leaf water extract and 1mL of kudzu vine root water extract, the filling adopts disposable brown bayonet bottle packaging, 10mL of each bottle, and the external plastic oral liquid packaging box is packaged. The half inhibition concentration IC50 of the oral liquid with the proportion to alpha-glucosidase is 0.407mg/mL, and the oral liquid has proper taste.
Table 1 shows the half inhibitory concentration IC50 of each of the formulations of examples 1-11 against alpha-glucosidase:
clinical study data: 200 clinical observation cases are observed, the age range of an observation population is 30-70 years, 100 cases of a test group and 100 cases of a blank group are included, 80 cases of hyperglycemia patients and 20 cases of type II diabetes patients are included in the test group, the oral liquid is drunk, each oral liquid is 10mL, the daily dosage is 3, and 1 patient is respectively drunk in the morning, the noon and the evening; blank group means that the oral liquid and other similar products for reducing blood sugar are not used.
The result shows that in 80 cases of the hyperglycemia patients of the testers, the blood sugar value of fasting blood sugar or two hours after meal is reduced by more than or equal to 10 percent and reaches 80 cases, accounting for 100 percent; in 20 cases of the diabetic patients in the test group, the blood sugar value of fasting blood sugar or two hours after meal is reduced by more than or equal to 10 percent to reach 19 cases, accounting for 95 percent; in 80 cases of patients with hyperglycemia in the blank group, the blood sugar value of fasting blood sugar or two hours after meal is reduced by more than or equal to 10 percent to reach 6 cases, accounting for 7.5 percent; in 20 cases of the blank group of diabetics, the blood sugar value of fasting blood sugar or two hours after meal is reduced by more than or equal to 10 percent to reach 1 case, accounting for 5 percent; comparing the results of the test group and the blank group, the curative effect of the test group is obviously better than that of the blank group.
Table 2 shows blood glucose values for five diabetic patients and two blank groups:
in the previous description, numerous specific details were set forth in order to provide a thorough understanding of the present invention. The foregoing description is only a preferred embodiment of the invention, which can be embodied in many different forms than described herein, and therefore the invention is not limited to the specific embodiments disclosed above. And that those skilled in the art may, using the methods and techniques disclosed above, make numerous possible variations and modifications to the disclosed embodiments, or modify equivalents thereof, without departing from the scope of the claimed embodiments. Any simple modification, equivalent change and modification of the above embodiments according to the technical essence of the present invention are within the scope of the technical solution of the present invention.
Claims (7)
1. An oral liquid for reducing blood sugar is characterized in that: is prepared from the following raw materials (by weight portion) tartary buckwheat 34.52-43.87%, sea-buckthorn 1.84-11.02%, kudzu vine root 0.05-2.21%, Siberian solomonseal rhizome 20.47-27.65%, cinnamon 20.64-27.65%, gynura divaricata 0.52-2.15%, mulberry leaf 0.15-0.61%, deionized water: and (4) the balance.
2. The oral liquid for reducing blood sugar according to claim 1, wherein: is prepared from (by weight) radix Et rhizoma Fagopyri Tatarici 41.64%, fructus Hippophae 6.94%, radix Puerariae 1.00%, rhizoma Polygonati 24.29%, cortex Cinnamomi 24.29%, herba Gei aleppici 1.55%, and folium Mori 0.28%.
3. The oral liquid for reducing blood sugar according to claim 1, wherein: is prepared from (by weight) radix Et rhizoma Fagopyri Tatarici 41.81%, fructus Hippophae 6.97%, radix Puerariae 1.00%, rhizoma Polygonati 24.39%, cortex Cinnamomi 24.39%, herba gynostemmatis segeti 1.17%, and folium Mori 0.28%.
4. The oral liquid for reducing blood sugar according to claim 1, wherein: is prepared from (by weight parts) radix Et rhizoma Fagopyri Tatarici 41.69%, fructus Hippophae 6.95%, radix Puerariae 1.00%, rhizoma Polygonati 24.32%, cortex Cinnamomi 24.32%, herba gynostemmatis segeti 1.17%, and folium Mori 0.56%.
5. A preparation method of the oral liquid for reducing blood sugar is characterized in that: the method comprises the following specific steps:
the method comprises the following steps: firstly, weighing the following raw materials, namely 15g of tartary buckwheat, 10g of sea-buckthorn, 7.2g of kudzu root, 5g of rhizoma polygonati, 5g of cinnamon, 2.8g of gynura divaricata and 2g of mulberry leaf;
step two: washing radix Et rhizoma Fagopyri Tatarici, fructus Hippophae, radix Puerariae, rhizoma Polygonati, cortex Cinnamomi, herba Chelidonii and folium Mori with water, drying at constant temperature for 6-8 hr at 75-85 deg.C for 3-5 times;
step three: respectively mechanically pulverizing radix Et rhizoma Fagopyri Tatarici, fructus Hippophae, radix Puerariae, rhizoma Polygonati, cortex Cinnamomi, herba Chelidonii and folium Mori to 80-100 mesh;
step four: adding 7 raw materials of tartary buckwheat, sea buckthorn, kudzu root, rhizoma polygonati, cinnamon, gynura divaricata and mulberry leaf into 7 beakers filled with 900mL of deionized water respectively, putting the beakers into an ultrasonic instrument for water extraction, repeatedly extracting for 2-4 times, combining filtrates, and concentrating to 100 mL.
Step five: sterilizing the tartary buckwheat, the sea buckthorn, the kudzuvine root, the rhizoma polygonati, the cinnamon, the gynura divaricata and the mulberry leaf solution respectively under the sterilization condition of 100-140 ℃ for 10-30 min.
Step six: mixing sterilized radix Et rhizoma Fagopyri Tatarici, fructus Hippophae, radix Puerariae, rhizoma Polygonati, cortex Cinnamomi, herba Chelidonii and folium Mori solution under aseptic condition, and packaging.
6. The method for preparing hypoglycemic oral liquid according to claim 5, wherein the hypoglycemic oral liquid comprises: drying the tartary buckwheat, the sea buckthorn, the kudzuvine root, the rhizoma polygonati, the cinnamon, the gynura divaricata and the mulberry leaves at 80 ℃ for 4 times at constant temperature for 8 hours each time; the grinding granularity of the tartary buckwheat, the sea buckthorn, the kudzuvine root, the rhizoma polygonati, the cinnamon, the gynura divaricata and the mulberry leaf is 100 meshes; respectively adding 7 raw materials of tartary buckwheat, sea buckthorn, kudzu vine root, rhizoma polygonati, cinnamon, gynura divaricata and mulberry leaf into 7 beakers filled with 900mL of deionized water, repeatedly extracting for 2 times, boiling for 1 time at 90 ℃, combining filtrates, and concentrating to 100 mL; the sterilization condition of the tartary buckwheat, the sea buckthorn, the kudzuvine root, the sealwort, the cinnamon, the gynura divaricata and the mulberry leaf solution is sterilization for 20min at 115 ℃; the tartary buckwheat, the sea buckthorn, the kudzuvine root, the rhizoma polygonati, the cinnamon, the gynura divaricata and the mulberry leaf solution are mixed and filled under the aseptic condition.
7. The method for preparing oral liquid for reducing blood sugar according to claim 6, wherein the method comprises the following steps: the oral liquid is packaged by adopting disposable brown bayonet bottles, each bottle is 10mL, and the oral liquid is packaged by an external plastic oral liquid packaging box.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010550842.XA CN111544386A (en) | 2020-06-16 | 2020-06-16 | Preparation method of oral liquid for reducing blood sugar |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010550842.XA CN111544386A (en) | 2020-06-16 | 2020-06-16 | Preparation method of oral liquid for reducing blood sugar |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111544386A true CN111544386A (en) | 2020-08-18 |
Family
ID=71997959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010550842.XA Pending CN111544386A (en) | 2020-06-16 | 2020-06-16 | Preparation method of oral liquid for reducing blood sugar |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111544386A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103584102A (en) * | 2013-11-20 | 2014-02-19 | 山西振东五和健康食品股份有限公司 | Health food with auxiliary effect in lowering blood sugar and preparation method of health food |
| CN109288054A (en) * | 2018-09-27 | 2019-02-01 | 盐城康林达生物科技有限公司 | A kind of hypoglycemic oral solution and preparation method thereof |
| CN110367422A (en) * | 2019-09-08 | 2019-10-25 | 李丽 | A kind of rhizoma polygonati mulberry leaf compound solid beverage and preparation method thereof |
-
2020
- 2020-06-16 CN CN202010550842.XA patent/CN111544386A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103584102A (en) * | 2013-11-20 | 2014-02-19 | 山西振东五和健康食品股份有限公司 | Health food with auxiliary effect in lowering blood sugar and preparation method of health food |
| CN109288054A (en) * | 2018-09-27 | 2019-02-01 | 盐城康林达生物科技有限公司 | A kind of hypoglycemic oral solution and preparation method thereof |
| CN110367422A (en) * | 2019-09-08 | 2019-10-25 | 李丽 | A kind of rhizoma polygonati mulberry leaf compound solid beverage and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107296949A (en) | Integration of drinking and medicinal herbs compound formulation and its preparation method and application | |
| CN103749816B (en) | Lotus leaf bitter gourd lipid-lowering health-care tea and preparation method thereof | |
| CN103099089A (en) | Health-care product for reducing blood sugar and blood pressure, relaxing bowels, losing weight, resisting fatigue and improving sexual function and production technology thereof | |
| CN111840363B (en) | Natto-assisted hypoglycemic health-care composition and preparation method and application thereof | |
| CN104856009A (en) | An eucommia ulmoides staminate flower health-care product | |
| CN109480281A (en) | A kind of organic black fruit fructus lycii ferment and preparation method thereof | |
| CN106266898A (en) | A kind of vital energy benefiting and the kidney invigorating, the compound preparation and preparation method thereof of defying age | |
| CN107156590A (en) | Vegetable solid beverage and preparation method thereof | |
| CN108713746A (en) | A kind of integration of drinking and medicinal herbs composition and its preparation method and application | |
| CN106343300A (en) | Plant beverage with flos rosae rugosae and method for preparing plant beverage | |
| CN107136245A (en) | A kind of pure draft fat-reducing tea bag health food and preparation method thereof | |
| CN103520318A (en) | Traditional Chinese medicine composition of enhancing immune function and preparation method of composition | |
| CN110731509A (en) | A health product containing prebiotics for lowering blood sugar and blood lipid, and its preparation method | |
| CN115089661A (en) | Application of ginseng composition for assisting in regulating endocrine metabolism and resisting and preventing cancer | |
| CN101062283B (en) | Tea for reducing blood sugar and its preparing method | |
| CN114145374A (en) | Astragalus membranaceus and corn stigma composite tea and preparation method and application thereof | |
| CN111544386A (en) | Preparation method of oral liquid for reducing blood sugar | |
| CN111227213A (en) | Honey with blood sugar regulating effect | |
| CN106551225A (en) | A kind of beverage and preparation method thereof | |
| CN111888431A (en) | Composition for treating diabetes and preparation method thereof | |
| CN112168944A (en) | Traditional Chinese medicine composition and extract for preventing new coronary pneumonia, and preparation method and application thereof | |
| CN110973303A (en) | Instant weight-reducing tea | |
| CN114848748B (en) | Composition with blood sugar reducing effect and preparation method thereof | |
| CN108379500A (en) | A kind of wheat seeding Chinese medicine composition that nourishing the liver Dealcoholic sobering-up is anti-halitosis and preparation method | |
| CN102940075A (en) | Tea substitute beverage |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200818 |